GLP-1 medications are among the most effective tools available for lowering A1C — and for many people with type 2 diabetes, the results go well beyond what older diabetes medications typically achieved.
How they work on blood sugar:
What kind of A1C improvement is realistic:
Meaningful reductions are common, particularly for people starting with elevated A1C. Some people see dramatic drops — moving from well into diabetic range to pre-diabetic or even normal range over the course of a year. Results vary based on starting A1C, dose, how long you've had diabetes, and lifestyle factors.
Ozempic vs. Mounjaro/Tirzepatide:
Tirzepatide (Mounjaro) targets both GLP-1 and GIP receptors, and tends to show stronger glycemic and weight outcomes than single-agonist options for many people — though individual response varies, and some do better switching medications than increasing doses.
Sustaining the gains:
A1C improvements are generally tied to staying on the medication. Some people maintain improvements after stopping if they've built lasting dietary habits, but this isn't guaranteed.
If glycemic control is a primary goal, **talk to your provider** about which medication and dose makes the most sense for your starting numbers.
Different ways people phrase this question. Each expands to the same answer.
GLP-1 medications are among the most effective tools available for lowering A1C — and for many people with type 2 diabetes, the results go well beyond what older diabetes medications typically achieved.
How they work on blood sugar:
What kind of A1C improvement is realistic:
Meaningful reductions are common, particularly for people starting with elevated A1C. Some people see dramatic drops — moving from well into diabetic range to pre-diabetic or even normal range over the course of a year. Results vary based on starting A1C, dose, how long you've had diabetes, and lifestyle factors.
Ozempic vs. Mounjaro/Tirzepatide:
Tirzepatide (Mounjaro) targets both GLP-1 and GIP receptors, and tends to show stronger glycemic and weight outcomes than single-agonist options for many people — though individual response varies, and some do better switching medications than increasing doses.
Sustaining the gains:
A1C improvements are generally tied to staying on the medication. Some people maintain improvements after stopping if they've built lasting dietary habits, but this isn't guaranteed.
If glycemic control is a primary goal, **talk to your provider** about which medication and dose makes the most sense for your starting numbers.
GLP-1 medications are among the most effective tools available for lowering A1C — and for many people with type 2 diabetes, the results go well beyond what older diabetes medications typically achieved.
How they work on blood sugar:
What kind of A1C improvement is realistic:
Meaningful reductions are common, particularly for people starting with elevated A1C. Some people see dramatic drops — moving from well into diabetic range to pre-diabetic or even normal range over the course of a year. Results vary based on starting A1C, dose, how long you've had diabetes, and lifestyle factors.
Ozempic vs. Mounjaro/Tirzepatide:
Tirzepatide (Mounjaro) targets both GLP-1 and GIP receptors, and tends to show stronger glycemic and weight outcomes than single-agonist options for many people — though individual response varies, and some do better switching medications than increasing doses.
Sustaining the gains:
A1C improvements are generally tied to staying on the medication. Some people maintain improvements after stopping if they've built lasting dietary habits, but this isn't guaranteed.
If glycemic control is a primary goal, **talk to your provider** about which medication and dose makes the most sense for your starting numbers.
GLP-1 medications are among the most effective tools available for lowering A1C — and for many people with type 2 diabetes, the results go well beyond what older diabetes medications typically achieved.
How they work on blood sugar:
What kind of A1C improvement is realistic:
Meaningful reductions are common, particularly for people starting with elevated A1C. Some people see dramatic drops — moving from well into diabetic range to pre-diabetic or even normal range over the course of a year. Results vary based on starting A1C, dose, how long you've had diabetes, and lifestyle factors.
Ozempic vs. Mounjaro/Tirzepatide:
Tirzepatide (Mounjaro) targets both GLP-1 and GIP receptors, and tends to show stronger glycemic and weight outcomes than single-agonist options for many people — though individual response varies, and some do better switching medications than increasing doses.
Sustaining the gains:
A1C improvements are generally tied to staying on the medication. Some people maintain improvements after stopping if they've built lasting dietary habits, but this isn't guaranteed.
If glycemic control is a primary goal, **talk to your provider** about which medication and dose makes the most sense for your starting numbers.